Ovarian cancer xenograft tumor response to trastuzumab and pertuzumab
Summary:
Analysis of SKOV3 ovarian cancer xenograft tumors treated with trastuzumab (TZ), pertuzumab (PZ), or both. TZ and PZ target Human Epidermal Growth Factor Receptor 2 (HER2). Combined therapy results in enhanced antitumor activity. Results provide insight into the molecular basis of this enhancement.
Sims AH, Zweemer AJ, Nagumo Y, Faratian D et al. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer 2012 May 22;106(11):1779-89. PMID: 22549178